Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia

References

1. 1.↵
   World Health Organization. Global tuberculosis report 2019. [Internet] Geneva (SW): World Health Organization; [Updated 2019. Cited 2020 Sept 24]. Available from: https://www.who.int/publications/i/item/global-tuberculosis-report-2019
2. 2.↵
   1. Metry AM,
   2. Al Salmi I,
   3. Al-Abri S,
   4. Al Ismaili F,
   5. Al Mahrouqi Y,
   6. Hola A, et al.

   Epidemiology and outcome of tuberculosis in immunocompromised patients. Saudi J Kidney Dis Transpl 2017; 28: 806–817.

   OpenUrl
3. 3.↵
   1. Gegia M,
   2. Winters N,
   3. Benedetti A,
   4. van Soolingen D,
   5. Menzies D.

   Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis 2017; 17: 223–234.

   OpenUrlCrossRef
4. 4.↵
   World Health Organization. Tuberculosis Country Profiles online tool. [Updated 2019. Cited 2020 Sept 24]. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&lan=%22EN%22&iso2=%22SA%22
5. 5.↵
   1. Somily AM,
   2. Naeem T,
   3. Habib HA,
   4. Sarwar MS,
   5. Kunimoto DY,
   6. Kambal AM.

   Changing epidemiology of tuberculosis detected by an 8-year retrospective laboratory study in a tertiary teaching hospital in central Saudi Arabia. Saudi Med J 2014; 35: 691–698.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Jiman-Fatani A,
   2. El-Hossary D,
   3. Eltahlawi RA.

   Mycobacterium tuberculosis complex: Detection and patterns of resistance to the first line anti-TB drugs at the King Abdulaziz University Hospital, Saudi Arabia. IAJAA 2016; 5: 2.

   OpenUrl
7. 7.↵
   1. Gibson J,
   2. Donnan E,
   3. Eather G.

   Management of rifampicin mono-resistant tuberculosis in Queensland, Australia: a retrospective case series. Respirol Case Rep 2018; 6: e00366.

   OpenUrl
8. 8.↵
   1. Almohaya A,
   2. Aldrees A,
   3. Akkielah L,
   4. Hashim AT,
   5. Almajid F,
   6. Binmoammar T, et al.

   Latent tuberculosis infection among health-care workers using Quantiferon-TB gold-plus in a country with a low burden for tuberculosis: prevalence and risk factors. Ann Saudi Med 2020; 40: 191–199.

   OpenUrl
9. 9.↵
   1. Menzies D,
   2. Adjobimey M,
   3. Ruslami R,
   4. Trajman A,
   5. Sow O,
   6. Kim H, et al.

   Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med 2018; 379: 440–453.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Dean AS,
    2. Zignol M,
    3. Cabibbe AM,
    4. Falzon D,
    5. Glaziou P,
    6. Cirillo DM, et al.

    Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS medicine 2020; 17: e1003008.

    OpenUrl
11. 11.↵
    1. Al-Tawfiq JA,
    2. Hinedi K,
    3. Memish ZA.

    Systematic review of the prevalence of Mycobacterium tuberculosis resistance in Saudi Arabia. J Chemother 2015; 27: 378–382.

    OpenUrl
12. 12.↵
    1. Khan MY,
    2. Kinsara AJ,
    3. Osoba AO,
    4. Wali S,
    5. Samman Y,
    6. Memish Z.

    Increasing antimicrobial resistance of M. tb in a Saudi Arabia referral hospital. Int J Antimicrob Agents 2001; 17: 415–418.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Abu-Amero KK.

    Status of antituberculosis drug resistance in Saudi Arabia 1979-98. East Mediterr Health J 2002; 8: 664–670.

    OpenUrlPubMed
14. 14.↵
    1. Chaudhry LA,
    2. Rambhala N,
    3. Al-Shammri AS,
    4. Al-Tawfiq JA.

    Patterns of antituberculous drug resistance in eastern Saudi Arabia: a 7-year surveillance study from 1/2003 to 6/2010. J Epidemiol Glob Health 2012; 2: 57–60.
15. 15.↵
    1. Cattamanchi A,
    2. Dantes RB,
    3. Metcalfe JZ,
    4. Jarlsberg LG,
    5. Grinsdale J,
    6. Kawamura LM, et al.

    Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48: 179–185.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.
    World Health Organization. Definitions and reporting framework for tuberculosis–2013 revision. [Updated 2021. Cited 2020 Sept 24]. Available from: https://www.who.int/tb/publications/definitions/en/
17. 17.
    1. Woods GL,
    2. Brown-Elliott BA,
    3. Conville PS,
    4. Desmond EP,
    5. Hall GS,
    6. Lin G, et al.

    Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; March 2011.
18. 18.
    1. Becton BD.

    Dickinson and Company Newsletter BD Bactec MGIT 960 SIRE kit now FDA-cleared for susceptibility testing of Mycobacterium tuberculosis. Microbiology News & Ideas. (Updated 2016. Updated 2016. Cited 2020 Feb 5) Available from URL: https://legacy.bd.com/ds/technicalCenter/inserts/8008200(04).pdf